- Home
- CNTA vs NTLA Comparison
CNTA vs NTLA Comparison
Compare CNTA & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- NTLA
- Stock Information
- Founded
- CNTA 2020
- NTLA 2014
- Country
- CNTA United Kingdom
- NTLA United States
- Employees
- CNTA N/A
- NTLA N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CNTA Health Care
- NTLA Health Care
- Exchange
- CNTA Nasdaq
- NTLA Nasdaq
- Market Cap
- CNTA 1.6B
- NTLA 794.5M
- IPO Year
- CNTA 2021
- NTLA 2016
- Fundamental
- Price
- CNTA $14.07
- NTLA $10.74
- Analyst Decision
- CNTA Strong Buy
- NTLA Buy
- Analyst Count
- CNTA 10
- NTLA 19
- Target Price
- CNTA $28.78
- NTLA $35.11
- AVG Volume (30 Days)
- CNTA 1.2M
- NTLA 4.9M
- Earning Date
- CNTA 08-12-2025
- NTLA 08-07-2025
- Dividend Yield
- CNTA N/A
- NTLA N/A
- EPS Growth
- CNTA N/A
- NTLA N/A
- EPS
- CNTA N/A
- NTLA N/A
- Revenue
- CNTA $15,000,000.00
- NTLA $45,569,000.00
- Revenue This Year
- CNTA N/A
- NTLA N/A
- Revenue Next Year
- CNTA N/A
- NTLA N/A
- P/E Ratio
- CNTA N/A
- NTLA N/A
- Revenue Growth
- CNTA 118.88
- NTLA N/A
- 52 Week Low
- CNTA $8.46
- NTLA $5.90
- 52 Week High
- CNTA $19.09
- NTLA $28.18
- Technical
- Relative Strength Index (RSI)
- CNTA 60.47
- NTLA 69.70
- Support Level
- CNTA $12.74
- NTLA $8.98
- Resistance Level
- CNTA $14.27
- NTLA $11.08
- Average True Range (ATR)
- CNTA 0.66
- NTLA 0.69
- MACD
- CNTA 0.12
- NTLA 0.16
- Stochastic Oscillator
- CNTA 85.57
- NTLA 88.96
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.